First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumours

Official Title

Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumours

Summary:

The purpose of this study is to determine whether a Monoclonal Antibody both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumours

Trial Description

Primary Outcome:

  • Incidence of Adverse Events (AEs)
  • Incidence of Serious Adverse Events (SAEs)
  • Incidence of AEs meeting protocol- defined dose-limiting toxicity (DLT) criteria
  • Incidence of AEs leading to discontinuation
  • Incidence of death
  • Incidence of clinically significant changes in clinical laboratory results: Hematology tests
  • Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
  • Incidence of clinically significant changes in clinical laboratory results: Urinalysis
  • Objective Response Rate (ORR)
  • Median Duration of Response (mDOR)
  • Progression Free Survival Rate (PFSR) by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1
Secondary Outcome:
  • ORR of BMS-986218 alone or in combination with Nivolumab
  • mDOR of BMS-986218 alone or in combination with Nivolumab
  • PFS of BMS-986218 alone or in combination with Nivolumab
  • Incidence of anti-drug antibody (ADA) to BMS-986218
  • Maximum observed serum concentration (Cmax)
  • Time of maximum observed concentration (Tmax)
  • Area under the concentration-time curve from time zero to the time of the
  • Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]
  • Trough observed serum concentration (Ctrough)
  • Total body clearance (CLT)
  • Average serum concentration over a dosing interval (AUC[TAU]/tau) at steady state (Css-avg)
  • Ratio of an exposure measure at steady state to that after the first dose [exposure measure includes AUC[TAU] and Cmax (AI)]
  • Terminal serum half-life if data permit (T-HALF)
  • Observed concentration at the end of a dosing interval (Ctau)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society